257 related articles for article (PubMed ID: 28283046)
1. Recommendations from the European Working Group for Value Assessment and Funding Processes in Rare Diseases (ORPH-VAL).
Annemans L; Aymé S; Le Cam Y; Facey K; Gunther P; Nicod E; Reni M; Roux JL; Schlander M; Taylor D; Tomino C; Torrent-Farnell J; Upadhyaya S; Hutchings A; Le Dez L
Orphanet J Rare Dis; 2017 Mar; 12(1):50. PubMed ID: 28283046
[TBL] [Abstract][Full Text] [Related]
2. Principles for consistent value assessment and sustainable funding of orphan drugs in Europe.
Gutierrez L; Patris J; Hutchings A; Cowell W
Orphanet J Rare Dis; 2015 May; 10():53. PubMed ID: 25935555
[TBL] [Abstract][Full Text] [Related]
3. Patients, payers and developers of Orphan Medicinal Products: lessons learned from 10 years' multi-stakeholder dialogue on improving access in Europe via MoCA.
Cavaller-Bellaubi M; Hughes-Wilson W; Kubinová Š; Van de Casteele M; Van Lente EJ; Degortes E; Pontén J; Eichler HG; Le Cam Y; Boselli S; Bucsics A
Orphanet J Rare Dis; 2023 Jun; 18(1):144. PubMed ID: 37308991
[TBL] [Abstract][Full Text] [Related]
4. Sustainable rare diseases business and drug access: no time for misconceptions.
Rollet P; Lemoine A; Dunoyer M
Orphanet J Rare Dis; 2013 Jul; 8():109. PubMed ID: 23879976
[TBL] [Abstract][Full Text] [Related]
5. Paying for the Orphan Drug System: break or bend? Is it time for a new evaluation system for payers in Europe to take account of new rare disease treatments?
Hughes-Wilson W; Palma A; Schuurman A; Simoens S
Orphanet J Rare Dis; 2012 Sep; 7():74. PubMed ID: 23013790
[TBL] [Abstract][Full Text] [Related]
6. Access and pricing of medicines for patients with rare diseases in the European Union: an industry perspective.
Tafuri G; Bracco A; Grueger J
Expert Rev Pharmacoecon Outcomes Res; 2022 Apr; 22(3):381-389. PubMed ID: 34930086
[TBL] [Abstract][Full Text] [Related]
7. The European challenges of funding orphan medicinal products.
Szegedi M; Zelei T; Arickx F; Bucsics A; Cohn-Zanchetta E; Fürst J; Kamusheva M; Kawalec P; Petrova G; Slaby J; Stawowczyk E; Vocelka M; Zechmeister-Koss I; Kaló Z; Molnár MJ
Orphanet J Rare Dis; 2018 Nov; 13(1):184. PubMed ID: 30396361
[TBL] [Abstract][Full Text] [Related]
8. An analysis of orphan medicine expenditure in Europe: is it sustainable?
Mestre-Ferrandiz J; Palaska C; Kelly T; Hutchings A; Parnaby A
Orphanet J Rare Dis; 2019 Dec; 14(1):287. PubMed ID: 31829218
[TBL] [Abstract][Full Text] [Related]
9. Novel approach to decision making for orphan drugs.
Decker B; Mlcoch T; Pustovalova A; Dolezal T
Int J Technol Assess Health Care; 2023 Feb; 39(1):e10. PubMed ID: 36748356
[TBL] [Abstract][Full Text] [Related]
10. Systematic review on the evaluation criteria of orphan medicines in Central and Eastern European countries.
Zelei T; Molnár MJ; Szegedi M; Kaló Z
Orphanet J Rare Dis; 2016 Jun; 11(1):72. PubMed ID: 27259284
[TBL] [Abstract][Full Text] [Related]
11. Does market exclusivity hinder the development of Follow-on Orphan Medicinal Products in Europe?
Brabers AE; Moors EH; van Weely S; de Vrueh RL
Orphanet J Rare Dis; 2011 Sep; 6():59. PubMed ID: 21892964
[TBL] [Abstract][Full Text] [Related]
12. HTA programme response to the challenges of dealing with orphan medicinal products: Process evaluation in selected European countries.
Nicod E; Annemans L; Bucsics A; Lee A; Upadhyaya S; Facey K
Health Policy; 2019 Feb; 123(2):140-151. PubMed ID: 28400128
[TBL] [Abstract][Full Text] [Related]
13. The work, goals, challenges, achievements, and recommendations of orphan medicinal product organizations in India: an interview-based study.
Choudhury MC; Saberwal G
Orphanet J Rare Dis; 2019 Nov; 14(1):241. PubMed ID: 31684990
[TBL] [Abstract][Full Text] [Related]
14. Orphan Medicine Incentives: How to Address the Unmet Needs of Rare Disease Patients by Optimizing the European Orphan Medicinal Product Landscape Guiding Principles and Policy Proposals by the European Expert Group for Orphan Drug Incentives (OD Expert Group).
Aartsma-Rus A; Dooms M; Le Cam Y
Front Pharmacol; 2021; 12():744532. PubMed ID: 34975469
[TBL] [Abstract][Full Text] [Related]
15. Orphan drugs, orphan diseases. The first decade of orphan drug legislation in the EU.
Joppi R; Bertele' V; Garattini S
Eur J Clin Pharmacol; 2013 Apr; 69(4):1009-24. PubMed ID: 23090701
[TBL] [Abstract][Full Text] [Related]
16. Value added medicines: what value repurposed medicines might bring to society?
Toumi M; Rémuzat C
J Mark Access Health Policy; 2017; 5(1):1264717. PubMed ID: 28265347
[No Abstract] [Full Text] [Related]
17. Are rare diseases still orphans or happily adopted? The challenges of developing and using orphan medicinal products.
Dear JW; Lilitkarntakul P; Webb DJ
Br J Clin Pharmacol; 2006 Sep; 62(3):264-71. PubMed ID: 16934041
[TBL] [Abstract][Full Text] [Related]
18. Evidence supporting regulatory-decision making on orphan medicinal products authorisation in Europe: methodological uncertainties.
Pontes C; Fontanet JM; Vives R; Sancho A; Gómez-Valent M; Ríos J; Morros R; Martinalbo J; Posch M; Koch A; Roes K; Oude Rengerink K; Torrent-Farnell J; Torres F
Orphanet J Rare Dis; 2018 Nov; 13(1):206. PubMed ID: 30442155
[TBL] [Abstract][Full Text] [Related]
19. Market access for medicines treating rare diseases: Association between specialised processes for orphan medicines and funding recommendations.
Fontrier AM
Soc Sci Med; 2022 Aug; 306():115119. PubMed ID: 35700552
[TBL] [Abstract][Full Text] [Related]
20. Dealing with Uncertainty and Accounting for Social Value Judgments in Assessments of Orphan Drugs: Evidence from Four European Countries.
Nicod E; Berg Brigham K; Durand-Zaleski I; Kanavos P
Value Health; 2017; 20(7):919-926. PubMed ID: 28712621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
